-

nihao guest [ sign in / register ]
2026-11-21 18:49:58


Zhang Q, Fouchier RAM, Moncada-Vélez M, Meijer A,. Autoantibodies against Type I Interferons and Death from H7N7 Avian Influenza. N Engl J Med. 2026 Nov 12;395(19):1963-1965
submited by kickingbird at Nov, 12, 2026 9:49 AM from N Engl J Med. 2026 Nov 12;395(19):1963-1965

Viruses emerging from zoonotic reservoirs are a major threat to humankind. From the time of the 1918 H1N1 “Spanish flu” pandemic, there have been four influenza A viruses, three coronaviruses, three hemorrhagic fever viruses, two retroviruses, and two paramyxoviruses that have crossed the species barrier and led to massive human-to-human transmission, with devastating consequences. Since the 1997 Hong Kong outbreak of H5N1 influenza, infections by 20 other avian influenza viruses in humans have been documented, albeit without sustained human-to-human transmission. In addition to the more than 1000 patients killed by H5N1, H7N9, and H5N6 virus infections worldwide, infections by four other strains (H7N7, H3N8, H9N2, and H10N8) have occasionally led to isolated deaths.
In this context, we recently reported autoantibodies neutralizing type I interferons in the first patient to die of H5N1 influenza in the United States. Another group reported an enrichment of autoantibodies neutralizing type I interferons in patients infected with H7N9 virus in China. This reported finding led us to search for autoantibodies neutralizing type I interferons in patients infected with H7N7 in the 2003 outbreak in the Netherlands. Among the 89 patients in whom H7N7 influenza was diagnosed was a 57-year-old male veterinary surgeon who died of the disease. The other 88 patients had had mild conjunctivitis or flu-like illness. We tested serum samples from 35 patients: the patient who died and 34 patients 13 to 59 years of age who had mild illness. We identified autoantibodies neutralizing interferon-α, -ω, and -β in the patient who died (Figure 1A) and autoantibodies neutralizing interferon-β in 2 of the 34 patients (5.7%), 30 and 35 years of age, who had mild illness (Figure 1B). The presence of autoantibodies neutralizing type I interferons in these three infected persons is unlikely to be a chance result, because autoantibodies neutralizing all three subtypes are generally absent in persons younger than 60 years of age, and autoantibodies neutralizing interferon-β are found in only 0.3% of persons in that age category.
Thus, autoantibodies neutralizing type I interferons may underlie human H7N7, H5N1, and H7N9 infections. The two deaths from H5N1 and H7N7 occurred in persons with neutralizing autoantibodies of multiple interferon subtypes. Autoantibodies neutralizing type I interferons are emerging as major, common, and global determinants of life-threatening disease caused by zoonotic viruses (e.g., avian influenza), emerging human viruses (e.g., severe acute respiratory syndrome coronavirus 2 and Middle East respiratory syndrome–related coronavirus during their initial emergence), epidemic viruses (e.g., seasonal influenza), viruses endemic in certain regions (e.g., West Nile virus, tickborne encephalitis virus, Usutu virus, Powassan virus, and Ross River virus), and live-attenuated viral vaccines (e.g., yellow fever and Chikungunya vaccines).
More alarmingly, the genome of the A/Netherlands/219/2003 strain isolated from serum samples in the fatal case reported here carried mutations causing 14 amino acid substitutions in viral proteins crucial for adaptation to humans (Table S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). The genome of the A/Louisiana/12/2024 strain isolated from the fatal case of H5N1 influenza we reported last year, in which serum samples from the patient tested positive for autoantibodies neutralizing type I interferons, carried similar mutations. Our findings suggest that defective type I interferon immunity enables zoonotic viruses to replicate in human cells, facilitating their adaptation to human hosts and increasing the possibility of human-to-human transmission. The two mild cases of H7N7 infection (in the 2003 Netherlands outbreak) in which the patients tested positive for autoantibodies neutralizing type I interferons suggest that the breach might occur stealthily in patients who have mild symptoms that do not trigger medical attention. These results and others that have been reported are consistent with the observation that persons with autoantibodies neutralizing type I interferons are at high risk for zoonotic viral infections. We hypothesize that such persons could potentially act as “patients zero” in emerging viral pandemics.

See Also:

Latest articles in those days:

[Go Top]    [Close Window]

Related Pages:
Learn about the flu news, articles, events and more
Subscribe to the weekly F.I.C newsletter!


  

Site map  |   Contact us  |  Term of use  |  FAQs |  粤ICP备10094839号-1
Copyright ©www.flu.org.cn. 2004-2026. All Rights Reserved. Powered by FIC 4.0.1
  Email:webmaster@flu.org.cn